MedTrace Logo

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

NCT00574704 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-07-11

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind, placebo-controlled setting

Conditions

  • Perennial Allergic Rhinoconjunctivitis
  • House Dust Mite Allergy

Interventions

DRUG

CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)

subcutaneous injections at 6 visits

DRUG

House dust mite allergen extract in combination with CYT003-QbG10-placebo

subcutaneous injections at 6 visits

DRUG

CYT003-AllQbG10 in combination with house dust mite allergen extract placebo

subcutaneous injections at 6 visits

DRUG

CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo

subcutaneous injections at 6 visits

Sponsors & Collaborators

  • Cytos Biotechnology AG

    lead INDUSTRY

Principal Investigators

  • Philipp Mueller, MD · Cytos Biotechnology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-03-31
Completion
2008-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00574704 on ClinicalTrials.gov